Exploring the impact of <scp>Cabotegravir‐Rilpivirine</scp> long‐acting on weight gain, body composition and quality of life in adults living with <scp>HIV</scp>
CAB + RPV LA was not associated with significant weight gain, clinically relevant changes in body composition or adverse metabolic effects over 48 weeks. Virologic suppression was maintained, renal laboratory parameters improved in prior INSTI users and treatment was well tolerated with increasing satisfaction. These findings support CAB + RPV LA as a safe, effective and metabolically neutral alternative to daily oral ART.
Authors
- Giulia Moi
- A De Vito
- S Uzzau
- Antonella Cano (ORCID: https://orcid.org/0000-0003-1544-9575)
- Franca Deriu
- Andrea Marongiu (ORCID: https://orcid.org/0000-0001-7038-3615)
- Agnese Colpani
- G Madeddu
- Maria Grazia Catte
- Maria Antonietta Deledda
- Mariangela V Puci
- A Spanu
- Giovanni Sotgiu
- Susanna Maria Nuvoli
Institutions
- University of Sassari (IT)
- Ospedale San Paolo (IT)
Publication Details
- Journal
- HIV Medicine
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1111/hiv.70202
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00